Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? (Q35195891)

7 August 2017

title

Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? (English)

1 reference

inflammatory bowel diseases

7 August 2017

0 references

0 references

probiotics

0 references

author name string

Kristin A Verbeke

series ordinal

1

1 reference

7 August 2017

Leen Boesmans

series ordinal

2

1 reference

7 August 2017

Eef Boets

series ordinal

3

1 reference

7 August 2017

publication date

27 June 2014

1 reference

Proceedings of the Nutrition Society

7 August 2017

published in

1 reference

7 August 2017

volume

73

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

490-497

1 reference

The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

GPR43/FFA2: physiopathological relevance and therapeutic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Nutritional protective mechanisms against gut inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Therapeutic potential of fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Enterotypes of the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Curbing our enthusiasm for fecal transplantation in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Fecal microbiota transplantation: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Therapeutic faecal microbiota transplantation: current status and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Probiotics--snake oil for the new millennium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Ecological control of the gastrointestinal tract. The role of probiotic flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Durable alteration of the colonic microbiota by the administration of donor fecal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Fecal microbiota transplantation: techniques, applications, and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

New therapies for inflammatory bowel disease: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Interactions between the microbiota and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Prebiotics in chronic intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

A human gut microbial gene catalogue established by metagenomic sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Probiotic VSL#3-induced TGF-β ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Probiotics for the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

The gut microbiota in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

The fundamental basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Diagnostics of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Mechanisms of probiotic actions - A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

New serologic markers for inflammatory bowel disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Recommendations for probiotic use-2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Saccharomyces boulardii does not prevent relapse of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

An overview of fecal microbiota transplantation: techniques, indications, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Manipulation of the bacterial flora in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Role of natural killer and dendritic cell crosstalk in immunomodulation by commensal bacteria probiotics

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial: Table 1

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

The long-term stability of the human gut microbiota

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

Probiotics and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

PPARγ in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665114000639

7 January 2021

10.1017/S0029665114000639

Identifiers

DOI

1 reference

7 August 2017

1 reference